Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro

Clinical and Experimental Metastasis

Volumn 18, Issue 2, 2000, Pages 171-178

  Balduyck, Malika ^a   Zerimech, Farid ^a   Gouyer, Valérie ^a   Lemaire, Raphael ^b   Hemon, Brigitte ^c   Grard, Georges ^a   Thiebaut, Carole ^a   Lemaire, Véronique ^a   Dacquembronne, Evelyne ^a   Duhem, Thérèse ^a   Lebrun, Anne ^a   Dejonghe, Marie José ^c   Huet, Guillemette ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSERM   (France)

Author keywords

Breast cancer cells; Invasiveness; Metalloproteinases; Synthetic inhibitors of metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

INTERSTITIAL COLLAGENASE; MATRIGEL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CELL CONTACT; CELL CULTURE; CELL MEMBRANE POTENTIAL; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

BASE SEQUENCE; BASEMENT MEMBRANE; BREAST NEOPLASMS; COLLAGEN; DNA PRIMERS; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYDROXAMIC ACIDS; LAMININ; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED;

EID: 0035115701     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006762425323     Document Type: Article

References (53)

1. Metalloproteinases and cancer invasion
2. Matrix metalloproteinases and their inhibitors in connective tissue remodeling
3. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3
4. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity
5. A matrix metalloproteinase expressed on the surface of invasive tumour cells
6. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP)
7. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease
8. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue
9. Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR
10. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer
11. Stromelysin 3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression
12. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
13. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas
14. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas
15. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
16. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer
17. High levels of TIMP-2 correlate with adverse prognosis in breast cancer
18. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
19. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression
20. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas
21. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
22. Matrix metalloproteinase-1 and -3 in breast cancer: Correlation with progesterone receptors and other clinicopathologic features
23. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer
24. Overview of matrix metalloproteinase expression in cultured human cells
25. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines
26. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines
27. MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells
28. Induction of metalloproteinase (MMPI) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells
29. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay
30. Genistein exerts multiple suppressive effects on human breast carcinoma cells
31. Inhibition of tumour cell invasion by protease inhibitors: Correlation with the protease profile
32. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases
33. Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines
34. Different mechanisms of regulation of the human stromelysin and collagenase genes. Analysis by a reverse-transcription-coupled-PCR assay
35. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma
36. Expression of MMP-7(PUMP-1) mRNA in human colorectal cancers
37. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis
38. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines
39. Regulation of matrix metalloproteinase expression in tumor invasion
40. Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals
41. Induction and repression of collagenase-1 by keratinocytes is controlled by distinct components of different extracellular matrix compartments
42. Integrin engagement regulates proliferation and collagenase expression of rheumatoid synovial fibroblasts
43. Implication of collagen type 1-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma
44. Anti-integrin antibodies induce type IV collagenase expression in keratinocytes
45. Anti-beta4 integrin antibodies enhance migratory and invasive abilities of human colon adenocarcinoma cells and their MMP-2 expression
46. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3
47. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity
48. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity
49. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13)
50. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate
51. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases
52. Cellular mechanisms for human procollagenase-3 (MMP-13) activation - Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme
53. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92.000 type IV collagenase secretion and in vitro invasion